Advertisement

The Biology and Natural History of Prostate Cancer: A Short Introduction

  • Lars HolmbergEmail author
  • Mieke Van Hemelrijck
Chapter
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 202)

Abstract

This chapter aims to serve as a quick glance outlining an overall picture of mainstream thoughts, and to serve as a point of departure for more thorough discussions. The introduction of PSA testing has immensely complicated research in prostate cancer epidemiology and biology and added new clinical and biological domains. As for many cancers, age and ethnic origin are the strongest known risk factors. While migrant studies imply that environment and/or personal life style is important, epidemiological studies have failed to establish any strong leads. Despite the known androgen dependence of prostate cancer, there is little to support that circulating levels of androgens, estrogens or 5-alpha-reductase are associated with risk of developing the disease. However, a consistent finding is a positive association with levels of Insulin-like Growth Factor-1 (IGF-1). Prostate cancer is one of the cancers most strongly related to inherited susceptibility, even when taking into account that family history of prostate cancer triggers PSA testing among relatives. A number of somatic genetic alterations (amplifications, deletions, point mutations, translocations) are associated with prostate cancer risk. Findings for alterations in FASN, HPN, AMACR and MYC have been fairly consistent. Recent research shows that the notion of “hormone-independent prostate cancer” has to be revised: most prostate cancers remain dependent on androgen receptor signalling also after progression despite traditional androgen deprivation therapy. Traditional markers of stage and type of disease still play a major role for prognostication and treatment decisions. Prostate cancer is one of the few cancers where patients have been recommended watchful waiting or active surveillance. This provides opportunities for studies of natural history of the disease. The understanding of prostate cancer aetiology and natural history has progressed slowly. However, the current situation is positively challenging and opens up possibilities for fruitful research.

Keywords

Prostate Cancer Active Surveillance Prostate Cancer Risk Watchful Waiting Androgen Receptor Signalling 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Alexander DD, Mink PJ, Cushing CA, Sceurman B (2010) A review and meta-analysis of prospective studies of red and processed meat intake and prostate cancer. Nutr J 9:50PubMedCentralPubMedCrossRefGoogle Scholar
  2. Alva A, Hussain M (2013) The changing natural history of metastatic prostate cancer. Cancer J 19(1):19–24Google Scholar
  3. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P et al (2008) Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27(3):253–63PubMedCentralPubMedCrossRefGoogle Scholar
  4. Baca SC, Garraway LA (2012) The genomic landscape of prostate cancer. Front Endocrinol (Lausanne) 3:69Google Scholar
  5. Bambury RM, Gallagher DJ. Prostate cancer: germline prediction for a commonly variable malignancy. BJU Int. 2012 Dec;110(11 Pt C):E809-18Google Scholar
  6. Barbieri CE, Bangma CH, Bjartell A, Catto JW, Culig Z, Gronberg H et al. (2013). The Mutational Landscape of Prostate Cancer. Eur Urol 64(4):567–76Google Scholar
  7. Benedettini E, Nguyen P, Loda M (2008) The pathogenesis of prostate cancer: from molecular to metabolic alterations. Diagn Histopathol (Oxf) 14(5):195–201CrossRefGoogle Scholar
  8. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C et al (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364(18):1708–17PubMedCrossRefGoogle Scholar
  9. Buschemeyer WC 3rd, Freedland SJ (2007) Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 52(2):331–43PubMedCrossRefGoogle Scholar
  10. Choudhury AD, Eeles R, Freedland SJ, Isaacs WB, Pomerantz MM, Schalken JA et al (2012) The role of genetic markers in the management of prostate cancer. Eur Urol 62(4):577–87PubMedCrossRefGoogle Scholar
  11. Davies NJ, Batehup L, Thomas R (2011) The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature. Br J Cancer 8(105 Suppl 1):S52–73CrossRefGoogle Scholar
  12. Gilbert R, Martin RM, Beynon R, Harris R, Savovic J, Zuccolo L et al (2011) Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. Cancer Causes Control 22(3):319–40PubMedCrossRefGoogle Scholar
  13. Green SM, Mostaghel EA, Nelson PS (2012) Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol 360(1–2):3–13PubMedCrossRefGoogle Scholar
  14. Gurel B, Iwata T, Koh CM, Yegnasubramanian S, Nelson WG, De Marzo AM (2008) Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets. Adv Anat Pathol 15(6):319–31Google Scholar
  15. Jeronimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ et al (2011) Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol 60(4):753–66PubMedCrossRefGoogle Scholar
  16. Klotz L (2012) Cancer overdiagnosis and overtreatment. Curr Opin Urol 22(3):203–9PubMedCrossRefGoogle Scholar
  17. Nacusi LP, Tindall DJ (2011) Targeting 5alpha-reductase for prostate cancer prevention and treatment. Nat Rev Urol 8(7):378–84PubMedCentralPubMedCrossRefGoogle Scholar
  18. Perry AS (2013) Prostate cancer epigenomics. J Urol 189(1):10–1PubMedCrossRefGoogle Scholar
  19. Popiolek M, Rider JR, Andren O, Andersson SO, Holmberg L, Adami HO et al (2013) Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol 63(3):428–35PubMedCrossRefGoogle Scholar
  20. Rajarubendra N, Lawrentschuk N, Bolton DM, Klotz L, Davis ID (2011) Prostate cancer immunology—an update for Urologists. BJU Int 107(7):1046–51PubMedCrossRefGoogle Scholar
  21. Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D et al (2010) Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 102(4):678–84PubMedCentralPubMedCrossRefGoogle Scholar
  22. Simard J, Dumont M, Soucy P, Labrie F (2002) Perspective: prostate cancer susceptibility genes. Endocrinology 143(6):2029–40PubMedCrossRefGoogle Scholar
  23. Szymanski KM, Wheeler DC, Mucci LA (2010) Fish consumption and prostate cancer risk: a review and meta-analysis. Am J Clin Nutr 92(5):1223–33PubMedCrossRefGoogle Scholar
  24. Tufts Evidence-based Practice Center (2011) An evidence review of active surveillance in men with localized prostate cancer. Agency for Healthcare Research and Quality. BostonGoogle Scholar
  25. Venkateswaran V, Klotz LH (2010) Diet and prostate cancer: mechanisms of action and implications for chemoprevention. Nat Rev Urol 7(8):442–53PubMedCrossRefGoogle Scholar
  26. Wilson KM, Giovannucci EL, Mucci LA (2012) Lifestyle and dietary factors in the prevention of lethal prostate cancer. Asian J Androl 14(3):365–74PubMedCrossRefGoogle Scholar
  27. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S et al (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367(3):203–13PubMedCentralPubMedCrossRefGoogle Scholar
  28. Yu C, Yao Z, Jiang Y, Keller ET (2012) Prostate cancer stem cell biology. (Minerva urologica e nefrologica) Ital J Urol Nephrol 64(1):19–33Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of Surgical SciencesUppsala University Regional Cancer Center University HospitalUppsalaSweden
  2. 2.School of Medicine Division of Cancer StudiesKing’s College LondonLondonUK

Personalised recommendations